Synergy Cancer Research Results

Synergy, Synergy: Click to Expand ⟱
Source:
Type:

Synergy — Interaction in which two or more agents, treatments, or biological interventions produce a combined effect greater than would be expected from their individual effects. In pharmacology and cancer research, synergy commonly refers to enhanced therapeutic efficacy when a compound is combined with chemotherapy, radiation, targeted therapy, or another bioactive agent.

Typical modulation in cancer: ↑ synergy is generally favorable when it increases tumor-cell killing, suppresses proliferation, enhances apoptosis or ferroptosis, or improves sensitivity to anticancer therapy. Synergy should be distinguished from simple additive effects and ideally supported by quantitative combination analysis such as combination index, Bliss independence, Loewe additivity, or related methods.

Typical modulation in Alzheimer’s disease: Context-dependent. Synergy may describe enhanced neuroprotective, anti-inflammatory, antioxidant, or cognitive effects produced by combinations of compounds or treatments, but it is not a disease-specific molecular pathway.
Scientific Papers found: Click to Expand⟱
6461- 1,8-Cin,    1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases
- Review, AD, NA - Review, Var, NA
*Inflam↓, *antiOx↑, *neuroP↑, *BioAv↑, *Half-Life↝, *toxicity↓, *PGE2↓, *TNF-α↓, *IL1β↓, *NO↓, *NF-kB↓, *PPARγ↓, COX2/PTGS2↓, *ROS↓, *SOD↑, *Catalase↑, *TAC↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *NADPH↑, *GPx↑, *AntiBio↑, *eff↑, *AntiFungal↑, *AntiViral↑, *TRPA1↑, Synergy↑, TumCCA↑, ROS↑, MAPK↝, mTOR↝, Apoptosis↑, survivin↓, Akt↓, p38↑, cl‑PARP↑, cl‑Casp3⇅, P53↑, BAX↑, Cyt‑c↑, Casp9↑, Dose↝, *Aβ↓, *tau↓, *GSK‐3β↓, *BACE/β-secretase↓, *cardioP↑, MFN2↑,
6462- 1,8-Cin,    Modes of Action of 1,8-Cineol in Infections and Inflammation
- Review, Var, NA - Review, AD, NA
*BioAv↑, *BBB↑, *AntiViral↑, *Bacteria↓, *AntiFungal↑, *Inflam↓, *BioAv↑, *MUC2↓, *MUC19↓, *NF-kB↓, *ICAM-1↓, *VCAM-1↓, DNAdam↑, *lipid-P↓, *PGE2↓, *IL4↓, *IL6↓, *IL1β↓, *IL6↓, Synergy↑, TGF-β↓, fascin↓, VEGF↓, MMP9↓, *MAPK↓, *ERK↓, JNK↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↑, *neuroP↑, *GSK‐3β↓, *AGEs↓, *BBB↑, *NLRP3↓,
2325- 2DG,    Research Progress of Warburg Effect in Hepatocellular Carcinoma
- Review, Var, NA
HK2↓, Glycolysis↓, PKM2↓, LDHA↓, TumCD↑, ChemoSen↑, Synergy↑,
1340- 3BP,    Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study
- Review, NA, NA
Glycolysis↓, HK2↓, LDH↓, OXPHOS↓, angioG↓, H2O2↑, Synergy↑,
1341- 3BP,    The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate
- Review, NA, NA
Glycolysis↓, OXPHOS↓, *toxicity↓, ROS↑, GSH↓, Synergy↑,
5272- 3BP,    The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells
- in-vitro, GBM, U87MG - in-vitro, Nor, HEK293
Glycolysis↓, ROS↑, GPx↓, eff↓, OXPHOS↓, HK2↓, ATP↓, ROS↑, ER Stress↑, BioAv↓, Cyt‑c↑, Synergy↑,
326- AgNPs,  TSA,    Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles
- in-vitro, Cerv, HeLa
Apoptosis↑, ChrMod↝, Synergy↑,
356- AgNPs,  MF,    Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study
- in-vitro, BC, MCF7 - in-vitro, Bladder, HTB-22
Apoptosis↑, P53↑, iNOS↑, NF-kB↑, Bcl-2↓, ROS↑, SOD↑, TumCCA↑, Synergy↑, Catalase↑, other↑,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, NA, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, Synergy↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
1158- And,  GEM,    Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer
TumCP↓, TumCCA↑, Apoptosis↑, STAT3↓, Akt↓, P21↑, BAX↑, cycD1/CCND1↓, cycE/CCNE↓, survivin↓, XIAP↓, Bcl-2↓, Synergy↑,
1348- And,    Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
- in-vitro, BC, MCF7 - in-vitro, BC, T47D - in-vivo, NA, NA
ERα/ESR1↓, TumCG↓, ROS↑, FOXM1↓, Synergy↑,
1152- Api,    Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
- Analysis, Nor, NA
*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, Synergy↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,
1547- Api,    Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading
- Review, NA, NA
angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, Synergy↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2/PTGS2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, ChemoSen↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, Synergy↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, Synergy↑, ChemoSen↑, ChemoSen↑, Synergy↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
1433- Ash,  SFN,    A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Synergy↑, Bcl-2↓, BAX↑, tumCV↓, DNMT1↓, DNMT3A↓, HDAC↓,
1525- Ba,  almon,    Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway
- in-vitro, Lung, H1975 - in-vivo, Lung, NA
Synergy↑, TumCP↓, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, cl‑Casp9↑, p‑PI3K↓, p‑Akt↓, ROS↑, eff↓,
1394- BBR,  DL,    Synergistic Inhibitory Effect of Berberine and d-Limonene on Human Gastric Carcinoma Cell Line MGC803
- in-vitro, GC, MGC803
Synergy↑, ROS↑, MMP↓, Casp3↑, Bcl-2↓, TumCCA↑,
1576- Citrate,    Targeting citrate as a novel therapeutic strategy in cancer treatment
- Review, Var, NA
TCA↓, T-Cell↝, Glycolysis↓, PKM2↓, PFK2?, SDH↓, PDH↓, β-oxidation↓, CPT1A↓, FASN↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, cl‑PARP↑, Hif1a↓, GLUT1↓, angioG↓, Ca+2↓, ROS↓, eff↓, Dose↓, Synergy↑, Mcl-1↓, HK2↓, IGF-1R↓, PTEN↑, citrate↓, Dose∅, ChemoSen↑, eff↑, eff↑, eff↑,
1572- Cu,    Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy
- Review, NA, NA
eff↑, Fenton↑, ROS↑, eff↑, mtDam↑, BAX↑, Bcl-2↓, MMP↓, Cyt‑c↑, Casp3↑, ER Stress↑, CHOP/DDIT3↑, Apoptosis↑, selectivity↑, Synergy↑, Pyro↑, Paraptosis↑, Cupro↑, ChemoSen↑, eff↑,
129- CUR,    Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation
- vitro+vivo, Pca, LNCaP
JNK↓, H3K4↓, TumCG↓, Apoptosis↑, Synergy↑,
130- CUR,    Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
BAD↝, BAX↝, Synergy↑,
12- CUR,    Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells
- in-vitro, MB, DAOY
HH↓, Shh↓, Gli1↓, PTCH1↓, cMyc↓, n-MYC↓, cycD1/CCND1↓, Bcl-2↓, NF-kB↓, Akt↓, β-catenin/ZEB1↓, survivin↓, Apoptosis↑, ChemoSen↑, RadioS↑, Synergy↑,
22- EGCG,    Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics
- in-vitro, PC, CD133+ - in-vitro, PC, CD44+ - in-vitro, PC, CD24+ - in-vitro, PC, ESA+
HH↓, Smo↓, PTCH1↓, PTCH2↓, Gli1↓, GLI2↓, Gli↓, Bcl-2↓, XIAP↓, Shh↓, survivin↓, Casp3↑, Casp7↑, CSCs↓, Nanog↓, cMyc↓, OCT4↓, EMT↓, Snail↓, Slug↓, Zeb1↓, TumCMig↓, TumCI↓, Synergy↑,
1503- EGCG,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
selectivity↑, DNMT1↓, RECK↑, MMPs↓, TumCI↓, angioG↓, TumMeta↓, HATs↓, IκB↑, NF-kB↓, IL6↓, COX2/PTGS2↓, NOS2↓, ac‑H3↑, ac‑H4↑, Synergy↑,
1322- EMD,    The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers
- Review, Var, NA
Apoptosis↑, TumCP↓, ROS↑, TumAuto↑, EMT↓, TGF-β↓, DNAdam↑, ER Stress↑, TumCCA↑, ATP↓, NF-kB↓, CYP1A1↑, STAC2↓, JAK↓, PI3K↓, Akt↓, MAPK↓, FASN↓, HER2/EBBR2↓, ChemoSen↑, Synergy↑, ChemoSen↑, angioG↓, VEGF↓, MMP2↓, eNOS↓, FOXD3↑, MMP9↓, TIMP1↑,
1435- GEN,  SFN,    The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
DNMTs↓, HDAC↓, Synergy↑, TumCCA↑, HMTs↓, HDAC2↓, HDAC3↓, KLF4↓, hTERT/TERT↓,
8544- Matr,    Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential
- Review, BC, NA
*hepatoP↑, *Inflam↓, *ROS↓, *ER Stress↓, *lipid-P↓, TumCP↓, TumCI↓, TumCMig↓, TumAuto↑, Apoptosis↑, *AST↓, *ALAT↓, *SOD↑, *MDA↓, *TNF-α↓, *IL6↓, *NRF2↑, *HO-1?, *NF-kB↓, *Inflam↓, AFP?, PCNA↓, cMyc↓, Bcl-2↓, BAX↑, EMT↓, MDM2↓, P53↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, NOTCH↑, ChemoSen↑, eff↑, survivin↓, XIAP↓, Synergy↑,
1043- MET,  immuno,    Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
- in-vitro, NA, NA
Synergy↑, PD-L1↓, Ki-67↑, TIM-3↑, L-sel↑,
523- MF,  MTX,    Extremely low-frequency magnetic fields significantly enhance the cytotoxicity of methotrexate and can reduce migration of cancer cell lines via transiently induced plasma membrane damage
- in-vitro, AML, THP1 - in-vitro, NA, PC12 - in-vivo, Cerv, HeLa
H2O2↑, TumCD↑, CellMemb↑, Synergy↑,
595- MFrot,  VitC,  MF,    The Effect of Alternating Magnetic Field Exposure and Vitamin C on Cancer Cells
- in-vitro, PC, MIA PaCa-2 - in-vitro, CRC, SW-620 - in-vitro, NA, HT1080 - in-vitro, Pca, PC3 - in-vitro, OS, U2OS - in-vitro, BC, MCF7 - in-vitro, Nor, CCD-18Co
TumCD↑, Synergy↑, *TumCG∅,
786- Mg,  VitC,    A narrative review on the role of magnesium in immune regulation, inflammation, infectious diseases, and cancer
Risk↓, *VitD↑, *pH↝, *ROS↓, TumCG↓, Synergy↑,
39- QC,    A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells
- Analysis, NA, NA
ROS↑, GSH↓, IL6↓, COX2/PTGS2↓, IL8↓, iNOS↓, TNF-α↓, MAPK↑, ERK↑, SOD↑, ATP↓, Casp↑, PI3K/Akt↓, mTOR↓, NOTCH1↓, Bcl-2↓, BAX↑, IFN-γ↓, TumCP↓, TumCCA↑, Akt↓, P70S6K↓, *Keap1↓, *GPx↑, *Catalase↑, *HO-1↑, *NRF2↑, NRF2↑, Synergy↑, HIF-1↓,
97- QC,  HPT,    Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo
- in-vitro, Pca, PC3
HSP72↑, TumCG↓, Synergy↑, ChemoSen↑, RadioS↑,
94- QC,  HPT,    Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, JCA-1
HSP70/HSPA5↓, TumCCA↑, TumCG↓, Synergy↑,
81- QC,  EGCG,    Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea
- in-vivo, Pca, NA
COMT↓, MRP1/ABCC1↓, Ki-67↓, Bax:Bcl2↑, AR↓, Akt↓, p‑ERK↓, COMT↓, Synergy↑, chemoPv↑, BioAv↑,
1391- RES,  BBR,    Effects of Resveratrol, Berberine and Their Combinations on Reactive Oxygen Species, Survival and Apoptosis in Human Squamous Carcinoma (SCC-25) Cells
- in-vitro, Tong, SCC25
ROS↑, Synergy↑,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
Synergy↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1465- SFN,    TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells
- NA, Bladder, NA
Synergy↑, Apoptosis↑, Casp↑, MMP↓, BID↑, DR5↑, ROS↑, NRF2↑, eff↑, eff↓,
1508- SFN,    Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment
- Review, Var, NA
*BioAv↑, HDAC↓, TumCCA↓, eff↓, Wnt↓, β-catenin/ZEB1↓, Casp12?, Bcl-2↓, cl‑PARP↑, Bax:Bcl2↑, IAP1↓, Casp3↑, Casp9↑, Telomerase↓, hTERT/TERT↓, ROS?, DNMTs↓, angioG↓, VEGF↓, Hif1a↓, cMYB↓, MMP1↓, MMP2↓, MMP9↓, ERK↑, E-cadherin↑, CD44↓, MMP2↓, Synergy↑, IL2↑, IFN-γ↑, IL1β↓, IL6↓, TNF-α↓, NF-kB↓, ERK↓, NRF2↑, RadioS↑, ChemoSideEff↓,
1478- SFN,  acet,    Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells
- in-vitro, Nor, NA
Synergy↑, NO↓, iNOS↓, COX2/PTGS2↓, IL1β↓, ROS↓,
1476- SFN,  PDT,    Enhancement of cytotoxic effect on human head and neck cancer cells by combination of photodynamic therapy and sulforaphane
- in-vitro, HNSCC, NA
Synergy↑, tumCV↓, ROS↑, eff↓, Casp↑,
1475- SFN,  Form,    Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway
- in-vitro, Cerv, HeLa
TumCP↓, PI3K↓, Akt↓, mTOR↓, Synergy↑, ROS↑,
1513- SFN,  acetaz,    Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
- in-vitro, BrCC, H720 - in-vivo, BrCC, NA - in-vitro, BrCC, H727
Synergy↑, tumCV↓, Apoptosis↑, P21↑, PI3K↓, Akt↓, mTOR↓, 5HT↓, NRF2↑,
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
Synergy↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,
1313- VitD3,  MEL,    The effects of melatonin and vitamin D3 on the gene expression of BCl-2 and BAX in MCF-7 breast cancer cell line
- in-vitro, BC, MCF7
BAX↑, Bcl-2↓, Bax:Bcl2↑, Synergy↑,

Showing Research Papers: 1 to 46 of 46

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 46

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   Catalase↑, 1,   CYP1A1↑, 1,   Fenton↑, 1,   Ferroptosis↑, 1,   frataxin↑, 1,   GPx↓, 1,   GSH↓, 3,   H2O2↑, 2,   MFN2↑, 1,   NRF2↓, 2,   NRF2↑, 5,   OXPHOS↓, 3,   ROS?, 1,   ROS↓, 2,   ROS↑, 21,   SIRT3↓, 1,   SOD↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 3,   BCR-ABL↓, 1,   MEK↓, 1,   MMP↓, 6,   Mortalin↓, 1,   mtDam↑, 1,   SDH↓, 1,   XIAP↓, 4,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑ACLY↓, 1,   citrate↓, 1,   cMyc↓, 3,   CPT1A↓, 1,   CYP3A4↓, 1,   FASN↓, 1,   FASN↑, 1,   Glycolysis↓, 5,   HK2↓, 4,   HMG-CoA↓, 1,   LDH↓, 1,   LDHA↓, 1,   NADPH↓, 1,   PDH↓, 1,   PFK2?, 1,   PI3K/Akt↓, 1,   PKM2↓, 2,   TCA↓, 1,   β-oxidation↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 14,   BAD↝, 1,   Bak↑, 1,   BAX↑, 10,   BAX↝, 1,   Bax:Bcl2↑, 4,   Bcl-2↓, 14,   Bcl-xL↓, 2,   BID↑, 1,   BIM↑, 2,   Casp↑, 3,   Casp12?, 1,   Casp2↑, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   cl‑Casp3⇅, 1,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 6,   cl‑Casp9↑, 1,   CK2↓, 1,   Cupro↑, 1,   Cyt‑c↑, 5,   DR4↑, 1,   DR5↑, 2,   Ferroptosis↑, 1,   hTERT/TERT↓, 2,   IAP1↓, 1,   iNOS↓, 2,   iNOS↑, 1,   JNK↓, 2,   MAPK↓, 1,   MAPK↑, 1,   MAPK↝, 1,   Mcl-1↓, 3,   MDM2↓, 1,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 1,   NOXA↑, 1,   p38↑, 1,   Paraptosis↑, 1,   Pyro↑, 1,   survivin↓, 7,   Telomerase↓, 2,   TumCD↑, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 11,   p‑Akt↓, 3,   FOXD3↑, 1,   HER2/EBBR2↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ChrMod↝, 1,   ac‑H3↑, 1,   H3K4↓, 1,   ac‑H4↑, 1,   HATs↓, 1,   other↑, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 3,   HSP70/HSPA5↓, 1,   HSP72↑, 1,   HSP90↓, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3B↑, 1,   p62↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 3,   DNMT1↓, 2,   DNMT3A↓, 1,   DNMTs↓, 2,   m-FAM72A↓, 1,   MGMT↓, 1,   P53↑, 4,   p‑P53↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 1,   SIRT6↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   P21↑, 2,   TumCCA↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   cMYB↓, 2,   CSCs↓, 3,   EMT↓, 8,   ERK↓, 2,   ERK↑, 2,   p‑ERK↓, 1,   FOXM1↓, 1,   FOXO3↑, 2,   Gli↓, 1,   Gli1↓, 2,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 4,   HDAC2↓, 1,   HDAC3↓, 1,   HH↓, 2,   HMTs↓, 1,   IGF-1R↓, 1,   KLF4↓, 1,   mTOR↓, 4,   mTOR↝, 1,   n-MYC↓, 1,   Nanog↓, 2,   NOTCH↑, 1,   NOTCH1↓, 1,   OCT4↓, 2,   P70S6K↓, 1,   PI3K↓, 6,   p‑PI3K↓, 1,   PTCH1↓, 2,   PTCH2↓, 1,   PTEN↑, 1,   Shh↓, 2,   Smo↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 6,   TumCG↑, 1,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

annexin II↓, 1,   Ca+2↓, 1,   E-cadherin↑, 2,   FAK↓, 2,   fascin↓, 1,   GLI2↓, 1,   ITGB1↓, 1,   ITGB3↓, 1,   Ki-67↓, 1,   Ki-67↑, 1,   L-sel↑, 1,   MMP1↓, 1,   MMP2↓, 5,   MMP9↓, 5,   MMPs↓, 3,   MUC1↑, 1,   RECK↑, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   ROCK1↓, 1,   Slug↓, 1,   Snail↓, 2,   STAC2↓, 1,   TGF-β↓, 2,   TIMP1↑, 1,   TumCI↓, 4,   TumCMig↓, 2,   TumCP↓, 8,   TumMeta↓, 2,   Vim↓, 2,   Zeb1↓, 2,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   EGFR↓, 2,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 5,   NO↓, 1,   VEGF↓, 4,  

Barriers & Transport(tgid=15) ⓘ

CellMemb↑, 1,   GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 5,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL1β↓, 2,   IL2↑, 1,   IL6↓, 3,   IL8↓, 1,   Inflam↓, 1,   IκB↑, 1,   JAK↓, 1,   NF-kB↓, 7,   NF-kB↑, 1,   PD-L1↓, 1,   T-Cell↝, 1,   TNF-α↓, 2,  

Cellular Microenvironment(tgid=17) ⓘ

TIM-3↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   COMT↓, 2,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 13,   CYP1A2↓, 1,   CYP2C9↓, 1,   Dose↓, 1,   Dose↝, 1,   Dose∅, 4,   eff↓, 8,   eff↑, 17,   Half-Life∅, 1,   MRP1/ABCC1↓, 1,   RadioS↑, 3,   selectivity↓, 1,   selectivity↑, 5,   Synergy↑, 47,  

Clinical Biomarkers(tgid=22) ⓘ

AFP?, 1,   AR↓, 1,   EGFR↓, 2,   ERα/ESR1↓, 1,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 3,   Ki-67↓, 1,   Ki-67↑, 1,   LDH↓, 1,   NOS2↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   chemoPv↑, 1,   ChemoSideEff↓, 1,   Risk↓, 1,   TumW↓, 1,  
Total Targets: 266

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   TRPA1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↑, 2,   GPx↑, 2,   HO-1?, 1,   HO-1↑, 2,   Keap1↓, 1,   lipid-P↓, 3,   MDA↓, 2,   NRF2↑, 3,   ROS↓, 4,   SOD↑, 2,   TAC↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   NADPH↑, 1,   PPARγ↓, 1,  

Cell Death(tgid=5) ⓘ

MAPK↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   GSK‐3β↓, 2,   TumCG∅, 1,  

Migration(tgid=13) ⓘ

VCAM-1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ICAM-1↓, 1,   IL1β↓, 2,   IL4↓, 1,   IL6↓, 3,   Inflam↓, 4,   MUC2↓, 1,   NF-kB↓, 3,   PGE2↓, 2,   TNF-α↓, 2,   VitD↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↝, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,   Aβ↓, 1,   BACE/β-secretase↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 4,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 3,   MUC19↓, 1,   VitD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 2,   toxicity↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 2,   AntiViral↑, 2,   Bacteria↓, 1,  
Total Targets: 57

Scientific Paper Hit Count for: Synergy, Synergy
9 Sulforaphane (mainly Broccoli)
4 Quercetin
3 3-bromopyruvate
3 Magnetic Fields
3 Apigenin (mainly Parsley)
3 Curcumin
3 EGCG (Epigallocatechin Gallate)
2 1,8-Cineole
2 Silver-NanoParticles
2 Andrographis
2 Metformin
2 Ashwagandha(Withaferin A)
2 Berberine
2 Citric Acid
2 Vitamin C (Ascorbic Acid)
2 Hyperthermia
1 2-DeoxyGlucose
1 Trichostatin A
1 Alpha-Lipoic-Acid
1 Gemcitabine (Gemzar)
1 Baicalein
1 almonertinib
1 D-limonene
1 Copper and Cu NanoParticles
1 Emodin
1 Genistein (soy isoflavone)
1 Matrine
1 immunotherapy
1 methotrexate
1 Magnetic Field Rotating
1 Magnesium
1 Resveratrol
1 acetaminophen
1 Photodynamic Therapy
1 Formononetin
1 acetazolamide
1 statins
1 Vitamin D3
1 Melatonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1849  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page